Optimizing Anti-Tumor Therapies with Engineered Antibodies

A type of immunotherapy uses antibodies that activate the TNF receptor family member CD40 on immune cells. CD40 is present on antigen-presenting cells (APCs) of the immune system and is activated by surface-bound proteins called CD40L. Activation of CD40 on APCs stimulates these cells to take up and display antigens to T and B cells, thereby stimulating an immune response. If the APCs display antigens present on tumor cells, then the subsequent T and B cell responses target the tumor cells. Application of antibodies that stimulate CD40 may increase the effectiveness of immunotherapies that target immune checkpoint inhibitors. Indeed, these antibodies may help convert an immune “cold” tumor into an immune “hot” target.

To stimulate an effective anti-tumor immune response, most of these antibodies bind to CD40 on the APC and a second binding partner on another cell. This second partner is another receptor called FcγRIIB. Like the TNF receptors, FcγRIIB is a member of a family of receptors, the Fc receptors. Fc receptors bind to the part of an antibody called the heavy chain. This part is the same in all antibodies of the same class. For example, IgG antibodies all have the same heavy chain and IgA antibodies have the same heavy chain, but the IgA heavy chain differs from the IgG heavy chain. Antibodies have another region that is variable, where the antigen is recognized (Figure 1). For antibodies that recognize CD40, CD40 is the antigen. If the antibody is an IgG class, then it will bind receptors of the FcγR type. There are 6 FcγR in humans. Unfortunately, the mouse and human Fc receptors are functionally different, making it difficult to test human antibodies in mice.

To overcome the challenge of testing human antibodies in mice, the Ravetch lab generated mice with the mouse genes for FcγRs replaced with those for humans. To study CD40 antibodies, the human form of CD40 was engineered into the mice with the human FcγRs. CD40-targeted antibodies modified to react with FcγRIIB instead of FcγRIIA, another member of the family, were more effective in stimulating an immune response and reducing tumors in the mice. The FcγRIIB clustered the antibodies and presented them in an ideal way to the APCs so that CD40 also clustered, stimulating a strong anti-tumor response that involved T cells. If the antibody engaged both FcγRIIB and FcγRIIA, this produced less of an activating signal for the anti-tumor immune response. Additionally, the mutated antibody likely promoted an interaction between the APCs and immune cells with a high abundance of FcγRIIB. Thus, not only was the modified antibody triggering a signal through clustered CD40, but it was also altering the cells that interacted together (Figure 2).

Based on this understanding of how the heavy chain of the antibody contributed to the anti-tumor immune response, Ravetch engineered a version of the antibody that had mutations in the heavy chain to optimize its interaction with FcγRIIB and minimize its interaction with FcγRIIA. The antibody is called APX005M, and the variable regions still interacted strongly with CD40. Because the amounts of FcγRIIB and FcγRIIA differs on the various types of immune cells, this engineered version of the CD40 antibody likely engages different immune cells to activate the CD40-positive APCs. The studies with the mice indicated that another benefit of APX005M was that this optimized antibody caused less adverse effects than the original CD40 antibodies that bound both Fc receptors. APX005M is now in clinical trials for several kinds of cancer, including those with poor prognosis (pancreatic cancer, melanoma, and brain cancers). The results of the initial Phase 1 safety trials are just beginning to be reported at conferences on cancer.

Intriguingly, this requirement for the antibody’s heavy chain to engage the Fc receptors appears to apply to many anti-cancer antibodies. Which Fc receptors the antibody binds affects how the antibody mediates an anti-tumor response. It is worth noting that the development of the optimized antibody from basic research into how the immune system recognizes and responds to antibodies took many years and involved the generation of an engineered mouse model. Another version of the mice with humanized Fc receptors was recently developed and is better suited for testing some aspects of cancer immunotherapies.

The knowledge of the complex interplay among the different cells of the immune system and how tumors avoid destruction is leading researchers to explore new treatment strategies. For example, giving a patient the CD40 antibody first so that the APCs re-activate T cells, then giving an inhibitor of the immune checkpoint to keep those T cells turned on may be more effective than simultaneous treatment or treatment with only one or the other type of immunotherapy.

Related Resources

Ravetch Laboratory, The Rockefeller University: https://www.rockefeller.edu/our-scientists/heads-of-laboratories/889-jeffrey-v-ravetch/ (accessed 5 September 2018)

Clinical Trials for APX0005M at clinicaltrials.gov https://www.clinicaltrials.gov/ct2/results?cond=&term=APX005M (accessed 5 September 2018)

F. Li, J. V. Ravetch, Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333, 1030-1034 (2011). PubMed

P. Smith, D. J. DiLillo, S. Bournazos, F. Li, J. V. Ravetch, Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc. Natl. Acad. Sci. U.S. A. 109, 6181–6186 (2012). PubMed

F. Li, J. V. Ravetch, Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement. Proc. Natl. Acad. Sci. U.S. A. 109, 10966-10971 (2012). PubMed

F. Li, J. V. Ravetch, Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo. Proc. Natl. Acad. Sci. U.S. A.110, 19501-19506 (2013). PubMed

D. J. Dilillo, J. V. Ravetch, Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 161, 1035-1045 (2015). PubMed

R. Dahan, B. C. Barnhart, F. Li, A. P. Yamniuk, A. J. Korman, Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective FcγR engagement. Cancer Cell 29, 820-831 (2016). PubMed

P. Bruhns, J.-L. Teillaud, Inhibitory IgG receptor-expressing cells: The must-have accessory for anti-CD40 immunomodulatory mAb efficacy. Cancer Cell 29, 771-773 (2018). PubMed

E. Casey, S. Bournazos, G. Mo, P. Mondello, K. S. Tan, J. V. Ravetch, D. A. Scheinberg, A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies. Leukemia 32, 547 (2018). PubMed

R. H. Vonderheide, The immune revolutions: A case for priming, not checkpoint. Cancer Cell 33, 563-569 (2018). PubMed

Cite this article:

 N. R. Gough, Optimizing anti-tumor therapies with engineered antibodies. BioSerendipity (18 September 2018) https://www.bioserendipity.com/optimizing-anti-tumor-therapies-with-engineered-antibodies/

Also of Interest in BioSerendipity

Immunotherapy Antagonists and Agonists

 

Building Better Antibodies